171 related articles for article (PubMed ID: 38057434)
1. Development of a nomogram to predict survival in advanced biliary tract cancer.
Imaoka H; Ikeda M; Nomura S; Morizane C; Okusaka T; Ozaka M; Shimizu S; Yamazaki K; Okano N; Sugimori K; Shirakawa H; Mizuno N; Satoi S; Yamaguchi H; Sugimoto R; Gotoh K; Sano K; Asagi A; Nakamura K; Ueno M
Sci Rep; 2023 Dec; 13(1):21548. PubMed ID: 38057434
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the effectiveness of chemotherapy combined with immunotherapy and chemotherapy alone in advanced biliary tract cancer and construction of the nomogram for survival prediction based on the inflammatory index and controlling nutritional status score.
Zhang Z; Wang D; Zhang J; Ruan Y; Zhao L; Yang L; Liu Z; Yang L; Lou C
Cancer Immunol Immunother; 2023 Nov; 72(11):3635-3649. PubMed ID: 37668711
[TBL] [Abstract][Full Text] [Related]
3. Gemcitabine-based chemotherapy for advanced biliary tract carcinomas.
Abdel-Rahman O; Elsayed Z; Elhalawani H
Cochrane Database Syst Rev; 2018 Apr; 4(4):CD011746. PubMed ID: 29624208
[TBL] [Abstract][Full Text] [Related]
4. Downsizing Chemotherapy for Initially Unresectable Locally Advanced Biliary Tract Cancer Patients Treated with Gemcitabine Plus Cisplatin Combination Therapy Followed by Radical Surgery.
Kato A; Shimizu H; Ohtsuka M; Yoshitomi H; Furukawa K; Takayashiki T; Nakadai E; Kishimoto T; Nakatani Y; Yoshidome H; Miyazaki M
Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S1093-9. PubMed ID: 26240009
[TBL] [Abstract][Full Text] [Related]
5. Predictive factors of the treatment outcome in patients with advanced biliary tract cancer receiving gemcitabine plus cisplatin as first-line chemotherapy.
Suzuki Y; Kan M; Kimura G; Umemoto K; Watanabe K; Sasaki M; Takahashi H; Hashimoto Y; Imaoka H; Ohno I; Mitsunaga S; Ikeda M
J Gastroenterol; 2019 Mar; 54(3):281-290. PubMed ID: 30298469
[TBL] [Abstract][Full Text] [Related]
6. Comparison of gemcitabine-based chemotherapies for advanced biliary tract cancers by renal function: an exploratory analysis of JCOG1113.
Ueno M; Morizane C; Okusaka T; Mizusawa J; Kataoka T; Ikeda M; Ozaka M; Okano N; Sugimori K; Todaka A; Shimizu S; Mizuno N; Yamamoto T; Sano K; Tobimatsu K; Katanuma A; Miyamoto A; Yamaguchi H; Nishina T; Shirakawa H; Kojima Y; Oono T; Kawamoto Y; Furukawa M; Iwai T; Sudo K; Miyakawa H; Yamashita T; Yasuda I; Takahashi H; Kato N; Shioji K; Shimizu K; Nakagohri T; Kamata K; Ishii H; Furuse J;
Sci Rep; 2021 Jun; 11(1):12885. PubMed ID: 34145336
[TBL] [Abstract][Full Text] [Related]
7. Single-institution experience with gemcitabine-cisplatin combination therapy as a second-line treatment for patients with unresectable biliary tract cancer after failure of gemcitabine-S-1 combination therapy: a prospective feasibility study.
Matsuyama R; Morioka D; Mori R; Hiratani S; Yabushita Y; Ota Y; Kumamoto T; Taniguchi K; Endo I
Cancer Chemother Pharmacol; 2018 May; 81(5):949-955. PubMed ID: 29594362
[TBL] [Abstract][Full Text] [Related]
8. Phase 2 study of copanlisib in combination with gemcitabine and cisplatin in advanced biliary tract cancers.
Tan ES; Cao B; Kim J; Al-Toubah TE; Mehta R; Centeno BA; Kim RD
Cancer; 2021 Apr; 127(8):1293-1300. PubMed ID: 33289918
[TBL] [Abstract][Full Text] [Related]
9. Nomogram for predicting survival in patients with unresectable and/or metastatic urothelial cancer who are treated with cisplatin-based chemotherapy.
Galsky MD; Moshier E; Krege S; Lin CC; Hahn N; Ecke T; Sonpavde G; Godbold J; Oh WK; Bamias A
Cancer; 2013 Aug; 119(16):3012-9. PubMed ID: 23720216
[TBL] [Abstract][Full Text] [Related]
10. Randomized phase III study of gemcitabine, cisplatin plus S-1 versus gemcitabine, cisplatin for advanced biliary tract cancer (KHBO1401- MITSUBA).
Ioka T; Kanai M; Kobayashi S; Sakai D; Eguchi H; Baba H; Seo S; Taketomi A; Takayama T; Yamaue H; Takahashi M; Sho M; Kamei K; Fujimoto J; Toyoda M; Shimizu J; Goto T; Shindo Y; Yoshimura K; Hatano E; Nagano H;
J Hepatobiliary Pancreat Sci; 2023 Jan; 30(1):102-110. PubMed ID: 35900311
[TBL] [Abstract][Full Text] [Related]
11. A multi-institution phase II study of gemcitabine/cisplatin/S-1 (GCS) combination chemotherapy for patients with advanced biliary tract cancer (KHBO 1002).
Kanai M; Hatano E; Kobayashi S; Fujiwara Y; Marubashi S; Miyamoto A; Shiomi H; Kubo S; Ikuta S; Yanagimoto H; Terajima H; Ikoma H; Sakai D; Kodama Y; Seo S; Morita S; Ajiki T; Nagano H; Ioka T
Cancer Chemother Pharmacol; 2015 Feb; 75(2):293-300. PubMed ID: 25477010
[TBL] [Abstract][Full Text] [Related]
12. Liposomal irinotecan plus fluorouracil and leucovorin versus fluorouracil and leucovorin for metastatic biliary tract cancer after progression on gemcitabine plus cisplatin (NIFTY): a multicentre, open-label, randomised, phase 2b study.
Yoo C; Kim KP; Jeong JH; Kim I; Kang MJ; Cheon J; Kang BW; Ryu H; Lee JS; Kim KW; Abou-Alfa GK; Ryoo BY
Lancet Oncol; 2021 Nov; 22(11):1560-1572. PubMed ID: 34656226
[TBL] [Abstract][Full Text] [Related]
13. Nal-IRI with 5-fluorouracil (5-FU) and leucovorin or gemcitabine plus cisplatin in advanced biliary tract cancer - the NIFE trial (AIO-YMO HEP-0315) an open label, non-comparative, randomized, multicenter phase II study.
Perkhofer L; Berger AW; Beutel AK; Gallmeier E; Angermeier S; Fischer von Weikersthal L; Goetze TO; Muche R; Seufferlein T; Ettrich TJ
BMC Cancer; 2019 Oct; 19(1):990. PubMed ID: 31646981
[TBL] [Abstract][Full Text] [Related]
14. A feasibility study of gemcitabine, S-1 and leucovorin combination therapy (GSL) for advanced biliary tract cancer.
Takahara N; Isayama H; Nakai Y; Sasaki T; Saito K; Sato T; Hakuta R; Ishigaki K; Saito T; Hamada T; Mizuno S; Kogure H; Tada M; Koike K
J Chemother; 2019 Sep; 31(5):284-289. PubMed ID: 31179889
[No Abstract] [Full Text] [Related]
15. A Multicenter Phase II Study of Gemcitabine plus S-1 Chemotherapy for Advanced Biliary Tract Cancer.
Arima S; Shimizu K; Okamoto T; Toki M; Suzuki Y; Okano N; Naruge D; Kawai K; Kobayashi T; Kasuga A; Kitamura H; Takasu A; Nagashima F; Sugiyama M; Furuse J
Anticancer Res; 2017 Feb; 37(2):909-914. PubMed ID: 28179351
[TBL] [Abstract][Full Text] [Related]
16. Gemcitabine and S-1 versus gemcitabine and cisplatin treatment in patients with advanced biliary tract cancer: a multicenter retrospective study.
Takahara N; Isayama H; Nakai Y; Sasaki T; Ishigaki K; Saito K; Akiyama D; Uchino R; Mizuno S; Yagioka H; Kogure H; Togawa O; Matsubara S; Ito Y; Toda N; Tada M; Koike K
Invest New Drugs; 2017 Jun; 35(3):269-276. PubMed ID: 28124197
[TBL] [Abstract][Full Text] [Related]
17. Prognostic nomogram for patients with unresectable pancreatic cancer treated with gemcitabine plus nab-paclitaxel or FOLFIRINOX: A post-hoc analysis of a multicenter retrospective study in Japan (NAPOLEON study).
Shibuki T; Mizuta T; Shimokawa M; Koga F; Ueda Y; Nakazawa J; Komori A; Otsu S; Arima S; Fukahori M; Makiyama A; Taguchi H; Honda T; Mitsugi K; Nio K; Ide Y; Ureshino N; Shirakawa T; Otsuka T
BMC Cancer; 2022 Jan; 22(1):19. PubMed ID: 34980029
[TBL] [Abstract][Full Text] [Related]
18. Nomogram to predict survival of patients with advanced and metastatic pancreatic Cancer.
Deng GC; Lv Y; Yan H; Sun DC; Qu TT; Pan YT; Han QL; Dai GH
BMC Cancer; 2021 Nov; 21(1):1227. PubMed ID: 34781928
[TBL] [Abstract][Full Text] [Related]
19. Prognostic and predictive factors for Taiwanese patients with advanced biliary tract cancer undergoing frontline chemotherapy with gemcitabine and cisplatin: a real-world experience.
Wu CE; Chou WC; Hsieh CH; Chang JW; Lin CY; Yeh CN; Chen JS
BMC Cancer; 2020 May; 20(1):422. PubMed ID: 32410631
[TBL] [Abstract][Full Text] [Related]
20. A nomogram model based on the number of examined lymph nodes-related signature to predict prognosis and guide clinical therapy in gastric cancer.
Li H; Lin D; Yu Z; Li H; Zhao S; Hainisayimu T; Liu L; Wang K
Front Immunol; 2022; 13():947802. PubMed ID: 36405735
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
